Fatigue News and Research

RSS

Updated results from Amgen’s blinatumomab Phase 2 study on ALL

Amgen today announced updated results from a Phase 2 study that showed treatment with blinatumomab (AMG 103) helped achieve a high-rate of complete response (CR) in 72 percent of adult patients with relapsed or refractory B-precursor acute lymphoblastic leukemia (ALL) treated in the study.

17 May 2012

Smoked cannabis may be an effective treatment for spasticity

A clinical study of 30 adult patients with multiple sclerosis (MS) at the University of California, San Diego School of Medicine has shown that smoked cannabis may be an effective treatment for spasticity - a common and disabling symptom of this neurological disease.

15 May 2012

Interim results from Seattle Genetics’ ADCETRIS phase II trial on CTCL

Seattle Genetics, Inc. today announced that interim results from an investigator-sponsored phase II clinical trial of ADCETRIS (brentuximab vedotin) in patients with relapsed cutaneous T-cell lymphoma (CTCL) were presented at the Society for Investigative Dermatology annual meeting being held May 9-12, 2012 in Raleigh, NC.

11 May 2012

Arthritis rates set to soar

According to new estimates the number of people with arthritis is set to soar with predictions that 1,500,000 Scots will be living with the condition by 2030.

10 May 2012

Brief empathy training program improves resident physicians interactions with patients

Resident physicians' participation in a brief training program designed to increase empathy with their patients produced significant improvement in how patients perceived their interactions with the residents.

8 May 2012

New analysis on why some soldiers never seek PTSD care

U.S. Army researcher Maj. Gary H. Wynn, M.D., shared new analysis on why some Soldiers suffering from combat-related post-traumatic stress disorder (PTSD) never seek care or drop out of treatment early during a presentation today at the American Psychiatric Association's annual meeting. His presentation, "Epidemiology of Combat-Related PTSD in U.S. Service Members: Lessons Learned," also described the approaches the Army is using to address this issue and improve overall patient outcomes.

8 May 2012

CardioKinetix Parachute Ventricular Partitioning Device trial data presented at 2012 EuroPCR

CardioKinetix Inc., a medical device company pioneering a catheter-based treatment for heart failure, today announced that clinical trial data from the first-of-its-kind Parachute Ventricular Partitioning Device for the treatment of patients with ischemic heart failure will be presented at the 2012 EuroPCR Conference in Paris.

7 May 2012

HiLo trial sets new gold standard for thyroid cancer treatment

The results of a large Cancer Research UK trial have set a new gold standard for treating thyroid cancer, reducing radiation doses to just one third of the current level, according to research in The New England Journal of Medicine.

3 May 2012

Tips to help homeowners tick-proof their yards

For more than 250,000 Americans, the bite of a deer tick meant the start of a life changing disease. With record warm temperatures and the start of May's National Lyme Disease Awareness Month, Mosquito Squad is on watch and has six tips to help homeowners tick-proof their yards.

2 May 2012

Misleading information about breast brachytherapy

One of the leading experts on radiation therapy for breast cancer says a new study in JAMA -- about breast cancer treatment - has misleading information and may unnecessarily deter women from getting breast brachytherapy, a safe and effective treatment.

2 May 2012

Excessive daytime sleepiness may cause learning, attention and behavior problems

Children who have learning, attention and behavior problems may be suffering from excessive daytime sleepiness, even though clinical tests show them sleeping long enough at night, a new study reports.

2 May 2012

Interferon linked with increased risk of depression in HCV patients

There's a high rate of depression among patients with hepatitis C, but a standard treatment for the disease includes a drug, interferon, that can cause depression.

2 May 2012

Pfizer receives FDA approval for Elelyso to treat Type 1 Gaucher disease

The U.S. Food and Drug Administration today approved Elelyso (taliglucerase alfa) for long-term enzyme replacement therapy to treat a form of Gaucher disease, a rare genetic disorder.

2 May 2012

MCC researchers aim to improve cancer patient's quality of life and care

Researchers at Moffitt Cancer Center have placed new emphasis on gathering data on cancer patient quality of life during both treatment and survivorship. Their focus is on gathering and using that data to develop interventions to improve the quality of life for patients in treatment and for cancer survivors.

30 Apr 2012

WCI sponsors 5th Annual Jean Sindab Triple Negative Breast Cancer Symposium

The 5th Annual Jean Sindab Triple Negative Breast Cancer Symposium, sponsored by the Winship Cancer Institute at Emory University, provides an intimate learning environment in which the most current advances in triple-negative breast cancers (TNBC) will be explored.

30 Apr 2012

Low-intensity workout may be effective in building muscle

Weight training at a lower intensity but with more repetitions may be as effective for building muscle as lifting heavy weights says a new opinion piece in Applied Physiology, Nutrition, and Metabolism.

27 Apr 2012

GSK receives FDA approval for Votrient to treat advanced soft tissue sarcoma

The U.S. Food and Drug Administration today approved Votrient (pazopanib) to treat patients with advanced soft tissue sarcoma who have previously received chemotherapy. Soft tissue sarcoma is a cancer that begins in the muscle, fat, fibrous tissue, and other tissues.

27 Apr 2012